236 related articles for article (PubMed ID: 30020405)
21. [Reversion of multidrug resistance of human gastric cancer SGC7901/DDP cells by E2F-1 gene silencing].
Lian C; Yang J; Wang X; Xie Y; Xiao Q
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):171-6. PubMed ID: 24785275
[TBL] [Abstract][Full Text] [Related]
22. Nuclear PIM1 confers resistance to rapamycin-impaired endothelial proliferation.
Walpen T; Kalus I; Schwaller J; Peier MA; Battegay EJ; Humar R
Biochem Biophys Res Commun; 2012 Dec; 429(1-2):24-30. PubMed ID: 23131564
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.
Feng R; Dong L
Int J Clin Exp Pathol; 2015; 8(6):6107-16. PubMed ID: 26261488
[TBL] [Abstract][Full Text] [Related]
24. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD
Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215
[TBL] [Abstract][Full Text] [Related]
25. Doxorubicin-induced alterations of c-myc and c-jun gene expression in rat glioblastoma cells: role of c-jun in drug resistance and cell death.
Pourquier P; Montaudon D; Huet S; Larrue A; Clary A; Robert J
Biochem Pharmacol; 1998 Jun; 55(12):1963-71. PubMed ID: 9714316
[TBL] [Abstract][Full Text] [Related]
26. The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells.
Kang Y; Park MA; Heo SW; Park SY; Kang KW; Park PH; Kim JA
Biochim Biophys Acta; 2013 Mar; 1830(3):2638-48. PubMed ID: 23246576
[TBL] [Abstract][Full Text] [Related]
27. PIM1 gene silencing inhibits proliferation and promotes apoptosis of human esophageal cancer cell line Eca-109.
Li JQ; Yang X; Zhou XM
Cancer Biomark; 2017; 18(2):149-154. PubMed ID: 27983525
[TBL] [Abstract][Full Text] [Related]
28. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Sasaki N; Kuroda J; Nagoshi H; Yamamoto M; Kobayashi S; Tsutsumi Y; Kobayashi T; Shimura Y; Matsumoto Y; Taki T; Nishida K; Horiike S; Akao Y; Taniwaki M
Exp Hematol; 2011 Aug; 39(8):817-28.e1. PubMed ID: 21640157
[TBL] [Abstract][Full Text] [Related]
29. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
[TBL] [Abstract][Full Text] [Related]
30. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.
Cotta CV; Leventaki V; Atsaves V; Vidaki A; Schlette E; Jones D; Medeiros LJ; Rassidakis GZ
Cancer; 2008 Feb; 112(3):552-61. PubMed ID: 18085637
[TBL] [Abstract][Full Text] [Related]
31. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.
Tekedereli I; Alpay SN; Tavares CD; Cobanoglu ZE; Kaoud TS; Sahin I; Sood AK; Lopez-Berestein G; Dalby KN; Ozpolat B
PLoS One; 2012; 7(7):e41171. PubMed ID: 22911754
[TBL] [Abstract][Full Text] [Related]
32. p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc.
Han JW; Dionne CA; Kedersha NL; Goldmacher VS
Cancer Res; 1997 Jan; 57(1):176-82. PubMed ID: 8988061
[TBL] [Abstract][Full Text] [Related]
33. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer.
Lv Z; Wei J; You W; Wang R; Shang J; Xiong Y; Yang H; Yang X; Fu Z
J Transl Med; 2017 Dec; 15(1):257. PubMed ID: 29258530
[TBL] [Abstract][Full Text] [Related]
34. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
35. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death.
Sagulenko V; Muth D; Sagulenko E; Paffhausen T; Schwab M; Westermann F
Carcinogenesis; 2008 Oct; 29(10):1869-77. PubMed ID: 18566016
[TBL] [Abstract][Full Text] [Related]
36. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
[TBL] [Abstract][Full Text] [Related]
37. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
38. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
39. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.
Forshell LP; Li Y; Forshell TZ; Rudelius M; Nilsson L; Keller U; Nilsson J
Oncotarget; 2011 Jun; 2(6):448-60. PubMed ID: 21646687
[TBL] [Abstract][Full Text] [Related]
40. PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway.
Cao L; Wang F; Li S; Wang X; Huang D; Jiang R
Cancer Lett; 2019 Mar; 444():116-126. PubMed ID: 30583073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
